Skip to content
OpenCapital
Get started

Enliven Therapeutics ELVN Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
——

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$3.41B+143%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0×0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enliven Therapeutics's interest income (expense), nonoperating?
Enliven Therapeutics (ELVN) reported interest income (expense), nonoperating of $4.2M in Q1 2026.
How has Enliven Therapeutics's interest income (expense), nonoperating changed year-over-year?
Enliven Therapeutics's interest income (expense), nonoperating increased by 31.3% year-over-year, from $3.2M to $4.2M.
What is the long-term trend for Enliven Therapeutics's interest income (expense), nonoperating?
Over 4 years (2021 to 2025), Enliven Therapeutics's interest income (expense), nonoperating has grown at a 187.9% compound annual growth rate (CAGR), from $233K to $16.01M.